Cullinan Therapeutics, Inc.

• Cullinan Therapeutics, Inc. Estimates – NASDAQ:CGEM
  TradingView · 23 Oct 2026
• Zipalertinib demonstrates clinical benefit in EGFR ex20ins NSCLC, Cullinan Therapeutics reports
  Traders Union · 19 Oct 2026
• Cullinan Therapeutics doses first patient in phase 2 AML study By Investing.com
  Investing.com India · 08 Oct 2026
• Cullinan Therapeutics doses first patient in Ph...
  Pluang · 08 Oct 2026
• Form 8K Cullinan Therapeutics, Inc For: 2 October By Investing.com
  Investing.com UK · 02 Oct 2026
• Cullinan Therapeutics starts NDA submission for zipalertinib plus chemo under FDA RTOR
  TradingView · 02 Oct 2026
• Cullinan Therapeutics begins FDA submission for zipalertinib combination
  Mugglehead Investment Magazine · 02 Oct 2026
• Cullinan Therapeutics' stock pullback offers a ...
  Pluang · 29 Sep 2026
• Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases
  Seeking Alpha · 29 Sep 2026
• Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
  TradingView · 28 Sep 2026
• Cullinan Therapeutics Highlights Fourth Quarter 2026
  GlobeNewswire · 24 Sep 2026
• Cullinan Therapeutics at stifel 2026 forum: autoimmune pipeline advances
  Investing.com · 24 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →